跳至主要内容
临床试验/NCT03234413
NCT03234413已完成不适用

Switching Between Different Types of Botulinum Toxin-A in Children With Cerebral Palsy Treated for Spasticity: a Safety Retrospective Evaluation

Nigar Dursun1 个研究点 分布在 1 个国家目标入组 118 人开始时间: 2017年7月30日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
118
试验地点
1
主要终点
Occurence of treatment related adverse events

研究概览

简要总结

Clinical guidelines recommend the use of Botulinum Toxin-A (BoNT-A) for localized/segmental spasticity in children with cerebral palsy. At the Kocaeli University (KOU) Department of Physical Medicine and Rehabilitation (PMR) more than 800 patients have been injected with the two approved toxinA types; OnabotulinumtoxinA or AbobotulinumtoxinA.

With this study investigators would like to evaluate retrospectively if switching from one toxin to another is safe as well as to evaluate if the efficacy when switching from one toxin to another was maintained.

详细描述

A data base was designed to capture all data that were considered relevant to the treatment evaluation. The data were transcribed directly from participants medical records. For the purpose of the study, data from the two subsequent visits where a different type of toxin was given will be collected and evaluated . In order to collect the pre and post status in terms of safety and efficacy, for each participant, data corresponding to the 6 previous and posterior months after the switch of the toxin will also be collected or data corresponding to the previous and posterior visit after the switch of the toxin will also be collected.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Retrospective

入排标准

年龄范围
2 Years 至 18 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • children diagnosis of cerebral palsy with respect to Rosenbaum criteria,
  • children having received repeated injections with two different types of toxinA treatment into their lower limb(s)

排除标准

  • children without repeated Botulinum toxin type A injections
  • children having received repeated injections with same type of toxinA

结局指标

主要结局

Occurence of treatment related adverse events

时间窗: Up to 30 months

Overall and per injection cycle

次要结局

  • Observational Gait Scale(Up to 30 months)
  • Modified Ashworth Scale(Up to 30 months)
  • Tardieu Scale(Up to 30 months)

研究者

发起方
Nigar Dursun
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Nigar Dursun

Professor, MD

Kocaeli University

研究点 (1)

Loading locations...

相似试验